Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value

Michaela R. Anderson, Peter B. Bach and Matthew R. Baldwin ()
Additional contact information
Michaela R. Anderson: Columbia University Irving Medical Center
Peter B. Bach: Memorial Sloan Kettering Cancer Center
Matthew R. Baldwin: Columbia University Irving Medical Center

PharmacoEconomics - Open, 2021, vol. 5, issue 1, No 14, 129-131

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00243-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00243-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00243-6

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().